{"transactions":[{"id":3502710,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Research & Development"}}],"security":"Restricted Stock Units","published_at":"2019-06-04T20:44:05.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":65920,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on such date and one-fourth on each anniversary thereafter."}],"balance_after":65920,"derivative":{"exercise_price":0,"exercise_date":"2020-06-03","expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":65920},"source":{"system":"sec-edgar","filing":"0001179110-19-007125","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019007125/edgar.xml","form_type":"4"}},{"id":3502709,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Research & Development"}}],"security":"Options to Purchase Common Stock","published_at":"2019-06-04T20:44:05.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":129358,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and 1/48 monthly thereafter."}],"balance_after":129358,"derivative":{"exercise_price":15.17,"exercise_date":"2020-06-03","expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":129358},"source":{"system":"sec-edgar","filing":"0001179110-19-007125","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019007125/edgar.xml","form_type":"4"}},{"id":3720965,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-12-21T12:53:20.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":45000,"price":20.99,"value":944550.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":3.01,"expiration_date":"2028-02-08","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-18-074356","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074356/a4.xml","form_type":"4"}},{"id":3720964,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-12-21T12:53:20.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":39999,"price":21.84,"value":873578.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":2.16,"expiration_date":"2027-02-02","underlying":"Common Stock","underlying_shares":39999},"source":{"system":"sec-edgar","filing":"0001104659-18-074356","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074356/a4.xml","form_type":"4"}},{"id":3720963,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-12-21T12:53:20.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":45788,"price":20.82,"value":953306.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":3.18,"expiration_date":"2026-02-04","underlying":"Common Stock","underlying_shares":45788},"source":{"system":"sec-edgar","filing":"0001104659-18-074356","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074356/a4.xml","form_type":"4"}},{"id":3720962,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-12-21T12:53:20.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":18.84,"value":471000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on July 31, 2016. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on July 31, 2016. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":5.16,"expiration_date":"2025-07-31","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-18-074356","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074356/a4.xml","form_type":"4"}},{"id":3720961,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-12-21T12:53:20.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":22500,"price":24,"value":540000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This RSU award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 8, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-074356","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074356/a4.xml","form_type":"4"}},{"id":3720960,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-12-21T12:53:20.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":20000,"price":24,"value":480000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This RSU award, which originally consisted of 40,000 RSUs and of which 20,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/2 annually over a period of 2 years beginning on October 4, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-074356","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074356/a4.xml","form_type":"4"}},{"id":3720959,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-12-21T12:53:20.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":15000,"price":24,"value":360000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This RSU award, which originally consisted of 20,000 RSUs and of which 5,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 2, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-074356","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074356/a4.xml","form_type":"4"}},{"id":3720958,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-12-21T12:53:20.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":5000,"price":24,"value":120000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This RSU award, which originally consisted of 10,000 RSUs and of which 5,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 4, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-074356","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074356/a4.xml","form_type":"4"}},{"id":3720957,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-12-21T12:53:20.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":5000,"price":24,"value":120000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This restricted stock unit (\"RSU\") award, which originally consisted of 20,000 RSUs and of which 15,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on July 31, 2016 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-074356","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074356/a4.xml","form_type":"4"}},{"id":3720956,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-12-21T12:53:20.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":10500,"price":24,"value":252000.0,"ownership":{"direct":false,"nature":"By daughter"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the \"Merger Agreement\"), by and among Endocyte, Inc. (the \"Company\"), Novartis AG (\"Novartis\") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis (\"Merger Sub\"), at the effective time (the \"Effective Time\") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-074356","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074356/a4.xml","form_type":"4"}},{"id":3720955,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-12-21T12:53:20.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":72253,"price":24,"value":1734072.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the \"Merger Agreement\"), by and among Endocyte, Inc. (the \"Company\"), Novartis AG (\"Novartis\") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis (\"Merger Sub\"), at the effective time (the \"Effective Time\") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-074356","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074356/a4.xml","form_type":"4"}},{"id":3720954,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-12-21T12:53:20.000Z","date":"2018-12-20","kind":"gift","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By daughter"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a gift of 10,500 shares by the reporting person to her daughter, who shares the reporting person's household."}],"balance_after":10500,"source":{"system":"sec-edgar","filing":"0001104659-18-074356","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074356/a4.xml","form_type":"4"}},{"id":3720953,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-12-21T12:53:20.000Z","date":"2018-12-20","kind":"gift","acquired":false,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a gift of 10,500 shares by the reporting person to her daughter, who shares the reporting person's household."}],"balance_after":139753,"source":{"system":"sec-edgar","filing":"0001104659-18-074356","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074356/a4.xml","form_type":"4"}},{"id":3724452,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-12-19T16:13:54.000Z","date":"2018-12-17","kind":"exercise","acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to this option vest 1/4 annually over a period of four years beginning February 2, 2018."}],"balance_after":39999,"derivative":{"exercise_price":2.16,"expiration_date":"2027-02-02","underlying":"Common Stock","underlying_shares":1},"source":{"system":"sec-edgar","filing":"0001179110-18-014134","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911018014134/edgar.xml","form_type":"4"}},{"id":3724451,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-12-19T16:13:54.000Z","date":"2018-12-17","kind":"exercise","acquired":false,"shares":14212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to this option vest 1/4 annually over a period of four years beginning February 4, 2017."}],"balance_after":45788,"derivative":{"exercise_price":3.18,"expiration_date":"2026-02-04","underlying":"Common Stock","underlying_shares":14212},"source":{"system":"sec-edgar","filing":"0001179110-18-014134","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911018014134/edgar.xml","form_type":"4"}},{"id":3724450,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-12-19T16:13:54.000Z","date":"2018-12-17","kind":"exercise","acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to this option vest 1/4 annually over a period of four years beginning July 31, 2016."}],"balance_after":25000,"derivative":{"exercise_price":5.16,"expiration_date":"2025-07-31","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001179110-18-014134","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911018014134/edgar.xml","form_type":"4"}},{"id":3724449,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-12-19T16:13:54.000Z","date":"2018-12-17","kind":"exercise","acquired":true,"shares":1,"price":2.16,"value":2.16,"ownership":{"direct":true},"balance_after":150253,"source":{"system":"sec-edgar","filing":"0001179110-18-014134","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911018014134/edgar.xml","form_type":"4"}},{"id":3724448,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-12-19T16:13:54.000Z","date":"2018-12-17","kind":"exercise","acquired":true,"shares":14212,"price":3.18,"value":45194.16,"ownership":{"direct":true},"balance_after":150252,"source":{"system":"sec-edgar","filing":"0001179110-18-014134","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911018014134/edgar.xml","form_type":"4"}},{"id":3724447,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-12-19T16:13:54.000Z","date":"2018-12-17","kind":"exercise","acquired":true,"shares":35000,"price":5.16,"value":180600.0,"ownership":{"direct":true},"balance_after":136040,"source":{"system":"sec-edgar","filing":"0001179110-18-014134","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911018014134/edgar.xml","form_type":"4"}},{"id":3794180,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-10-09T14:21:27.000Z","date":"2018-10-05","kind":"sale","acquired":false,"shares":9111,"price":15.5579,"value":141748.0269,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of 9,111 shares in multiple transactions, ranging in price from $15.1400 to $15.9150, resulting in a weighted-average sale price per share of $15.5579. The 9,111 shares were sold to cover taxes, commissions and fees associated with the October 4, 2018 settlement of 20,000 restricted stock units in the form of Company common stock on a one-for-one basis. The shares were sold by Merrill Lynch pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934 adopted by the reporting person on August 1, 2018."}],"balance_after":101040,"source":{"system":"sec-edgar","filing":"0001179110-18-012092","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911018012092/edgar.xml","form_type":"4"}},{"id":3854866,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-08-02T16:05:04.000Z","date":"2018-08-01","kind":"sale","acquired":false,"shares":1414,"price":15.9756,"value":22589.4984,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of 1,414 shares in multiple transactions, ranging in price from $15.9600 to $16.0500, resulting in a weighted-average sale price per share of $15.9756. The 1,414 shares were sold to cover taxes, commissions and fees associated with the July 31, 2018 settlement of 5,000 restricted stock units in the form of Company common stock on a one-for-one basis. The shares were sold by Merrill Lynch pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934 adopted by the reporting person on August 1, 2018."}],"balance_after":110151,"source":{"system":"sec-edgar","filing":"0001179110-18-010127","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911018010127/edgar.xml","form_type":"4"}},{"id":4070196,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-08T16:43:51.000Z","date":"2018-02-08","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the option vest 1/4 annually over a period of 4 years beginning on 2/8/19."}],"balance_after":45000,"derivative":{"exercise_price":3.01,"expiration_date":"2028-02-08","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001179110-18-001809","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911018001809/edgar.xml","form_type":"4"}},{"id":4070195,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-02-08T16:43:51.000Z","date":"2018-02-08","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that will vest and be paid 1/4 annually over a period of 4 years beginning on 2/8/19 in the form of one share of common stock for each restricted stock unit."}],"balance_after":111565,"source":{"system":"sec-edgar","filing":"0001179110-18-001809","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911018001809/edgar.xml","form_type":"4"}},{"id":4190149,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-10-06T17:08:37.000Z","date":"2017-10-04","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that will vest and be paid 1/2 annually over a period of 2 years beginning on October 4, 2018, in the form of one share of common stock for each restricted stock unit."}],"balance_after":89065,"source":{"system":"sec-edgar","filing":"0001179110-17-013183","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911017013183/edgar.xml","form_type":"4"}},{"id":4463845,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-02-07T19:26:00.000Z","date":"2017-02-04","kind":"tax_withholding","acquired":false,"shares":935,"price":2.18,"value":2038.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations associated with the settlement of 2,500 restricted stock units in the form of Company common stock on a one-for-one basis on February 4, 2017."}],"balance_after":49065,"source":{"system":"sec-edgar","filing":"0001179110-17-001933","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911017001933/edgar.xml","form_type":"4"}},{"id":4468184,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-02-03T15:49:23.000Z","date":"2017-02-02","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the option vest 1/4 annually over a period of 4 years beginning on February 2, 2018."}],"balance_after":40000,"derivative":{"exercise_price":2.16,"expiration_date":"2027-02-02","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001179110-17-001598","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911017001598/edgar.xml","form_type":"4"}},{"id":4468183,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":157002,"kind":"person","name":"Armour Alison A.","position":1,"cik":"0001646726","reported_name":"Armour Alison A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-02-03T15:49:23.000Z","date":"2017-02-02","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that will vest and be paid 1/4 annually over a period of 4 years beginning on February 2, 2018, in the form of one share of common stock for each restricted stock unit."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001179110-17-001598","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911017001598/edgar.xml","form_type":"4"}}]}